Compare Stocks: SVRA, ELVN, RLAY, and LEGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELVN Enliven Therapeutics	$59.32 -0.6%	$55.66	$14.78 ▼ $62.32	$4.37B	0.3	790,280 shs	1.11 million shs
LEGN Legend Biotech	$21.52 -1.1%	$22.72	$16.24 ▼ $37.50	$4.21B	0.4	2.08 million shs	811,970 shs
RLAY Relay Therapeutics	$19.04 +0.2%	$19.36	$3.86 ▼ $21.27	$4.17B	1.69	2.38 million shs	2.05 million shs
SVRA Savara	$5.37	$5.65	$3.34 ▼ $7.01	$1.10B	0.25	1.56 million shs	625,207 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELVN Enliven Therapeutics	+1.08%	-1.40%	-2.39%	+71.85%	+184.73%
LEGN Legend Biotech	-0.64%	+6.10%	+13.70%	-33.32%	-39.50%
RLAY Relay Therapeutics	+2.70%	-2.11%	-2.71%	+40.61%	+362.53%
SVRA Savara	-1.65%	-2.19%	-0.74%	+5.50%	+57.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELVN Enliven Therapeutics	$59.32 -0.6%	$55.66	$14.78 ▼ $62.32	$4.37B	0.3	790,280 shs	1.11 million shs
LEGN Legend Biotech	$21.52 -1.1%	$22.72	$16.24 ▼ $37.50	$4.21B	0.4	2.08 million shs	811,970 shs
RLAY Relay Therapeutics	$19.04 +0.2%	$19.36	$3.86 ▼ $21.27	$4.17B	1.69	2.38 million shs	2.05 million shs
SVRA Savara	$5.37	$5.65	$3.34 ▼ $7.01	$1.10B	0.25	1.56 million shs	625,207 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELVN Enliven Therapeutics	+1.08%	-1.40%	-2.39%	+71.85%	+184.73%
LEGN Legend Biotech	-0.64%	+6.10%	+13.70%	-33.32%	-39.50%
RLAY Relay Therapeutics	+2.70%	-2.11%	-2.71%	+40.61%	+362.53%
SVRA Savara	-1.65%	-2.19%	-0.74%	+5.50%	+57.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELVN Enliven Therapeutics	2.78	Moderate Buy	$75.00	26.43% Upside
LEGN Legend Biotech	2.47	Hold	$53.43	148.27% Upside
RLAY Relay Therapeutics	2.93	Moderate Buy	$25.92	36.12% Upside
SVRA Savara	2.88	Moderate Buy	$10.14	88.88% Upside

Current Analyst Ratings Breakdown

Latest SVRA, ELVN, RLAY, and LEGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$65.00
9/4/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
9/1/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	RLAY Relay Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/20/2026	RLAY Relay Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $29.00
8/18/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	ELVN Enliven Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/18/2026	ELVN Enliven Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$78.00
8/18/2026	ELVN Enliven Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$62.00 ➝ $73.00
8/14/2026	RLAY Relay Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$28.00 ➝ $31.00
8/12/2026	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $49.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$12.22 per share	N/A
LEGN Legend Biotech	$1.03B	4.05	N/A	N/A	$6.35 per share	3.39
RLAY Relay Therapeutics	$15.35M	271.82	N/A	N/A	$4.06 per share	4.69
SVRA Savara	N/A	N/A	N/A	N/A	$0.70 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELVN Enliven Therapeutics	-$103.69M	-$1.67	N/A	N/A	N/A	N/A	-18.55%	-18.09%	11/11/2026 (Estimated)
LEGN Legend Biotech	-$296.80M	-$0.25	N/A	18.39	N/A	-7.21%	-8.71%	-5.40%	11/11/2026 (Estimated)
RLAY Relay Therapeutics	-$276.48M	-$1.57	N/A	N/A	N/A	N/A	-42.27%	-38.67%	11/5/2026 (Estimated)
SVRA Savara	-$118.84M	-$0.58	N/A	N/A	N/A	N/A	-90.28%	-68.95%	11/11/2026 (Estimated)

Latest SVRA, ELVN, RLAY, and LEGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.07	$0.09	+$0.02	$0.18	$355.96 million	$387.50 million
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A
8/6/2026	Q2 2026	RLAY Relay Therapeutics	-$0.3911	-$0.41	-$0.0189	-$0.41	$0.96 million	$0.35 million
8/5/2026	Q2 2026	ELVN Enliven Therapeutics	-$0.3872	-$0.49	-$0.1028	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELVN Enliven Therapeutics	N/A	64.07	64.07
LEGN Legend Biotech	N/A	3.04	2.94
RLAY Relay Therapeutics	N/A	18.27	18.27
SVRA Savara	0.21	10.13	10.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELVN Enliven Therapeutics	95.08%
LEGN Legend Biotech	70.89%
RLAY Relay Therapeutics	96.98%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
ELVN Enliven Therapeutics	3.00%
LEGN Legend Biotech	0.02%
RLAY Relay Therapeutics	5.04%
SVRA Savara	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELVN Enliven Therapeutics	50	73.27 million	71.07 million	Optionable
LEGN Legend Biotech	2,965	193.77 million	193.73 million	Optionable
RLAY Relay Therapeutics	330	219.14 million	208.10 million	Optionable
SVRA Savara	20	205.46 million	194.57 million	Optionable

SVRA, ELVN, RLAY, and LEGN Headlines

Recent News About These Companies

Jupiter Topco LLC Invests $2.88 Million in Savara Inc. $SVRA

September 3 at 3:44 AM | marketbeat.com

BlackRock Inc. Takes $76.97 Million Position in Savara Inc. $SVRA

August 31, 2026 | marketbeat.com

6,976,810 Shares in Savara Inc. $SVRA Purchased by Nantahala Capital Management LLC

August 29, 2026 | marketbeat.com

Analysts Set Savara Inc. (NASDAQ:SVRA) PT at $10.14

August 27, 2026 | americanbankingnews.com

Algert Global LLC Purchases 464,645 Shares of Savara Inc. $SVRA

August 27, 2026 | marketbeat.com

ADAR1 Capital Management LLC Purchases New Shares in Savara Inc. $SVRA

August 26, 2026 | marketbeat.com

Spruce Street Capital LP Acquires New Shares in Savara Inc. $SVRA

August 25, 2026 | marketbeat.com

Deutsche Bank AG Makes New $5.33 Million Investment in Savara Inc. $SVRA

August 25, 2026 | marketbeat.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...

August 24, 2026 | uk.finance.yahoo.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

August 24, 2026 | businesswire.com

Savara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from Analysts

August 24, 2026 | marketbeat.com

Savara Inc. (SVRA) Latest Press Releases & Corporate News - Yahoo Finance

August 20, 2026 | finance.yahoo.com

Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA

August 15, 2026 | marketbeat.com

Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen

August 15, 2026 | marketbeat.com

HC Wainwright Brokers Lower Earnings Estimates for Savara

August 14, 2026 | marketbeat.com

Savara (NASDAQ:SVRA) Stock Price Down 5.4% - What's Next?

August 13, 2026 | marketbeat.com

HC Wainwright Has Pessimistic View of Savara FY2029 Earnings

August 13, 2026 | marketbeat.com

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026 | caledonianrecord.comC

Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

August 11, 2026 | marketbeat.com

Savara Inc. $SVRA Shares Bought by Renaissance Technologies LLC

August 8, 2026 | marketbeat.com

Savara (SVRA) to Announce Quarterly Earnings on Wednesday

August 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA, ELVN, RLAY, and LEGN Company Descriptions

Enliven Therapeutics NASDAQ:ELVN

$59.32 -0.33 (-0.55%)

As of 04:00 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Legend Biotech NASDAQ:LEGN

$21.52 -0.23 (-1.06%)

As of 04:00 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Relay Therapeutics NASDAQ:RLAY

$19.04 +0.03 (+0.16%)

As of 04:00 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Savara NASDAQ:SVRA

$5.37 0.00 (0.00%)

As of 04:00 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SVRA, ELVN, RLAY, and LEGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SVRA, ELVN, RLAY, and LEGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SVRA, ELVN, RLAY, and LEGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA, ELVN, RLAY, and LEGN Company Descriptions

Enliven Therapeutics NASDAQ:ELVN

Legend Biotech NASDAQ:LEGN

Relay Therapeutics NASDAQ:RLAY

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SVRA, ELVN, RLAY, and LEGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SVRA, ELVN, RLAY, and LEGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SVRA, ELVN, RLAY, and LEGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA, ELVN, RLAY, and LEGN Company Descriptions

Enliven Therapeutics NASDAQ:ELVN

Legend Biotech NASDAQ:LEGN

Relay Therapeutics NASDAQ:RLAY

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools